Christensen Jakob Wedel Sells 700 Shares of Illumina (NASDAQ:ILMN) Stock

Key Points

• Christensen Jakob Wedel, Illumina's senior vice president, sold 700 shares on May 6 at an average price of $139.04 under a pre-arranged Rule 10b5-1 plan, cutting his stake by 4.44% to 15,056 shares valued at about $2.09 million.
• Illumina beat Q1 estimates with $1.15 EPS on $1.09 billion revenue and set FY2026 guidance of $5.15–$5.30 EPS; the stock recently traded near $138.71 with a market cap around $21 billion, while analysts hold a consensus "Hold" rating and a $131.06 price target.

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) SVP Christensen Jakob Wedel sold 700 shares of Illumina stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares of the company's stock, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

Shares of NASDAQ ILMN traded down $3.87 during midday trading on Thursday, hitting $138.71. 1,240,929 shares of the company's stock were exchanged, compared to its average volume of 1,874,600. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12 month low of $75.24 and a 12 month high of $155.53. The company's 50 day moving average price is $126.55 and its 200 day moving average price is $127.56. The firm has a market capitalization of $20.99 billion, a PE ratio of 25.22, a price-to-earnings-growth ratio of 2.30 and a beta of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the company posted $0.97 EPS. The firm's revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Institutional Trading of Illumina

A number of institutional investors have recently modified their holdings of the stock. Elyxium Wealth LLC bought a new position in Illumina in the 4th quarter valued at about $25,000. Board of the Pension Protection Fund bought a new position in Illumina in the 4th quarter valued at about $26,000. Creative Capital Management Investments LLC increased its holdings in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock valued at $26,000 after buying an additional 120 shares during the period. TD Waterhouse Canada Inc. bought a new position in Illumina in the 4th quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC bought a new position in Illumina in the 4th quarter valued at about $26,000. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ILMN has been the subject of several recent research reports. Piper Sandler reduced their price target on Illumina from $195.00 to $170.00 and set an "overweight" rating for the company in a research note on Monday, February 9th. Guggenheim boosted their price target on Illumina from $144.00 to $170.00 and gave the company a "buy" rating in a research note on Monday, January 26th. TD Cowen restated a "hold" rating on shares of Illumina in a research note on Wednesday, January 7th. Robert W. Baird set a $137.00 price target on Illumina in a research note on Friday, February 6th. Finally, Stifel Nicolaus boosted their price target on Illumina from $135.00 to $155.00 and gave the company a "buy" rating in a research note on Tuesday, January 20th. Six research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Illumina has a consensus rating of "Hold" and a consensus price target of $131.06.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.